These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 26140560)

  • 1. Early phase cancer clinical trials: design, ethics and future directions.
    Coupe N; Gupta A; Lord SR
    Br J Hosp Med (Lond); 2015 Jul; 76(7):409-13. PubMed ID: 26140560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose selection in phase I studies: why we should always go for the top.
    Sleijfer S; Wiemer E
    J Clin Oncol; 2008 Apr; 26(10):1576-8. PubMed ID: 18332465
    [No Abstract]   [Full Text] [Related]  

  • 3. Dose selection in phase I studies: why we should always go for the most effective.
    Haines IE
    J Clin Oncol; 2008 Jul; 26(21):3650-2; author reply 3652-3. PubMed ID: 18640947
    [No Abstract]   [Full Text] [Related]  

  • 4. The changing landscape of phase I trials in oncology.
    Wong KM; Capasso A; Eckhardt SG
    Nat Rev Clin Oncol; 2016 Feb; 13(2):106-17. PubMed ID: 26552953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Choice of designs and doses for early phase trials.
    Zhou Y
    Fundam Clin Pharmacol; 2004 Jun; 18(3):373-8. PubMed ID: 15147290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ethical and Policy Issues for Seamless Phase I Oncology Trials.
    Hutchinson N; Vinarov E; Iasonos A; Kimmelman J
    J Clin Oncol; 2020 Mar; 38(7):669-673. PubMed ID: 31877086
    [No Abstract]   [Full Text] [Related]  

  • 7. The development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials.
    Calvert AH; Plummer R
    Clin Cancer Res; 2008 Jun; 14(12):3664-9. PubMed ID: 18559580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-limiting toxicity and maximum tolerated dose: still fit for purpose?
    Wong HH; Halford S
    Lancet Oncol; 2015 Oct; 16(13):1287-8. PubMed ID: 26433816
    [No Abstract]   [Full Text] [Related]  

  • 9. Statistical designs for early phases of cancer clinical trials.
    Guan S
    J Biopharm Stat; 2012; 22(6):1109-26. PubMed ID: 23075011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review: new biological insights in early clinical studies.
    Maur M; Sessa C
    Hematol Oncol; 2007 Jun; 25(2):53-7. PubMed ID: 17351979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Phase I cancer trials methodology].
    Le Tourneau C; Faivre S; Raymond E; Diéras V
    Bull Cancer; 2007 Nov; 94(11):943-51. PubMed ID: 18055311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small-sample behavior of novel phase I cancer trial designs.
    Oron AP; Hoff PD
    Clin Trials; 2013 Feb; 10(1):63-80. PubMed ID: 23345304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I cancer trials: limitations and implications.
    Dillman RO; Koziol JA
    Mol Biother; 1992 Sep; 4(3):117-21. PubMed ID: 1445664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three-dose-cohort designs in cancer phase I trials.
    Huang B; Chappell R
    Stat Med; 2008 May; 27(12):2070-93. PubMed ID: 17764082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.
    Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G
    Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Methodological approaches of clinical studies with targeted therapies].
    Penel N; Saleron J; Lansiaux A; Clisant S; Adenis A; Fournier C; Duhamel A; Bonneterre J
    Bull Cancer; 2008 Feb; 95(2):185-90. PubMed ID: 18304903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials.
    Gupta S; Hunsberger S; Boerner SA; Rubinstein L; Royds R; Ivy P; LoRusso P
    J Natl Cancer Inst; 2012 Dec; 104(24):1860-6. PubMed ID: 23169991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Innovations in phase 1 trial design: where do we go next?
    Collins JM
    Clin Cancer Res; 2000 Oct; 6(10):3801-2. PubMed ID: 11051221
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: Dose escalation methods in phase I cancer clinical trials.
    Zohar S; O'Quigley J
    J Natl Cancer Inst; 2009 Dec; 101(24):1732-3; author reply 1733-5. PubMed ID: 19893006
    [No Abstract]   [Full Text] [Related]  

  • 20. Practical modifications of the continual reassessment method for phase I cancer clinical trials.
    Faries D
    J Biopharm Stat; 1994 Jul; 4(2):147-64. PubMed ID: 7951271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.